- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00068991
HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, China
A Cluster-Randomized Trial to Evaluate the Efficacy of a Combined Individual- and Community-Based Behavioral Intervention to Improve Quality of Life for HIV-Positive Villagers in Rural China (China CIPRA Project 2)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
A previous study found that HIV-infected villagers in Anhui Province, China describe their quality of life as poor. While poverty, poor health, stigma, and discrimination contribute to this poor quality of life, all these issues are interrelated and deserve further investigation. The quality of life for HIV-infected people may be made better through education, either for HIV-infected people to learn more about HIV, the treatments they are receiving, and how to deal with their disease, or for HIV uninfected people to understand HIV infection and to reduce stigma and discrimination associated with HIV infection. This study will provide skills training to HIV-infected adults and anti-stigma and anti-discrimination training to influential community members. The purpose of this study is to evaluate the changes in quality of life in HIV-infected villagers living in Anhui Province, China that result after these two training programs are administered.
There will be 3 groups in this study. Group 1 participants will be HIV-infected villagers. Group 1 participants will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will also be asked to bring a family member to each training session. After completing training, participants will be asked to complete a post-training evaluation of the training sessions. Group 1 participants will be asked to complete questionnaires at study entry and 6 and 12 months after completion of training.
Group 2 participants will be villagers considered influential members of their community. In the first 2 months of the study, Group 2 participants will take part in four, 2-hour training sessions focusing on anti-stigma and anti-discrimination messages. Group 2 participants will also attend additional support meetings monthly, from Months 2 to 15. Group 2 participants will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
Group 3 participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training, to determine changing community attitudes about HIV as a result of Group 2's training. There will be no additional study visits or training for Group 3 participants.
Tipo de estudio
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Beijing, Porcelana, 100050
- Chinese Center for Disease Control and Prevention
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria for All Participants:
- Live in one of the fourteen administrative villages in Funan County or Yingzhou District, Anhui Province, China
Inclusion Criteria for Group 1:
- HIV-infected
- Willing and able to take part in all study visits
- Willing and able to provide contact information for locator purposes
- Willing and able to bring a family member to training sessions
Inclusion Criteria for Group 2:
- Considered an influential member of their community
- Willing and able to take part in all training and follow-up support meetings
Inclusion Criteria for Group 3:
- Willing to complete the cross-sectional survey
Exclusion Criteria for All Study Participants:
- Spent more than 6 months outside of the community in the year prior to study entry
- Permanent disability (e.g., deafness, serious mental illness, mental retardation) that would interfere with the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: 1
Participants will be HIV-infected villagers and will will take part in 2-hour skills training sessions every week from study entry to Week 8. Participants will bring a family member to each training session.
After training, participants complete a post-training evaluation of the training sessions.
Participants will also complete questionnaires at study entry and 6 and 12 months after completion of training.
|
Two-hour weekly skills training sessions followed by evaluation questionnaire
|
Experimental: 2
Participants will be villagers considered influential members of their community.
In the first 2 months of the study, Participants will take part in four 2-hour training sessions focusing on anti-stigma and anti-discrimination messages.
Participants will also attend additional support meetings monthly, from Months 2 to 15.
They will be evaluated before and after their training sessions to determine the improvements in knowledge and attitudes about HIV among group participants.
|
Two-hour training sessions focusing on anti-stigma and anti-discrimination
|
Experimental: 3
Participants will be randomly selected community members and will complete a cross-sectional survey at study entry and 6 and 12 months after Group 2's completion of training to determine changing community attitudes about HIV as a result of Group 2's training.
There will be no additional study visits or training for Group 3 participants.
|
Survey evaluation of community attitudes towards HIV
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Medical Outcomes Study HIV Health Survey (MOS-HIV) score in-HIV infected participants
Periodo de tiempo: Throughout study
|
Throughout study
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Level of stigma among community members, as determined by HIV knowledge score and HIV attitudes and stigmatizing behaviors reported
Periodo de tiempo: Throughout study
|
Throughout study
|
Emotional well-being of HIV-infected participants, as determined by perceived support scale and stigma scale scores
Periodo de tiempo: Throughout study
|
Throughout study
|
Self-efficacy score in HIV-infected participants
Periodo de tiempo: Throughout study
|
Throughout study
|
Knowledge of correct condom use score among HIV-infected participants
Periodo de tiempo: Throughout study
|
Throughout study
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Investigador principal: Zunyou Wu, MD, PhD, Centers for Disease Control and Prevention, China
- Investigador principal: Jie Xu, MD, MS, Centers for Disease Control and Prevention, China
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones por virus de ARN
- Enfermedades virales
- Infecciones
- Infecciones transmitidas por la sangre
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Enfermedades del sistema inmunológico
- Infecciones por VIH
Otros números de identificación del estudio
- CIPRA Project 2
- 1U19AI051915-01 (Subvención/contrato del NIH de EE. UU.)
- CIPRA CH 002
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infecciones por VIH
-
Icahn School of Medicine at Mount SinaiIRRASReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán